CLINICAL TRIALS & RESEARCH

Thoracic, Head & Neck Protocols

• Lung Cancer (NSCLC) (RWH 07-349-32):A Phase I Study of Anti-CD3 x Cetuximab-Armed Activated T Cells, Low Dose IL2, and GM-CSF for EGFR-Positive, Advanced Non-Small Cell Lung Cancer
• Head and Neck Cancer (ECOG 1305): Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
• NSCLC (RWH # 379-30): A Phase I Study of Dasatinib With Concurrent Chemoradiation for Stage III NSCLC

Contact information

• Robin Davies, B.A., B.S.N., R.N.
  RWMC Protocol Office Manager
  Phone: (401) 456-2268 - Fax: (401) 456-2658 - rdavies@rwmc.org
• Frances D’Allesandro, C.C.R.P.
  Clinical Research Coordinator, RWMC Protocol Office
  Phone: (401) 456-2698 - Fax: (401) 456-2658 - fdallesandro@rwmc.org
• Jessica Donaghy A.S.
  Administrative Associate, RWMC Protocol Office
  Phone: (401) 456-5393 - Fax: (401) 456-2658 - jdonaghy@rwmc.org